|12 Months Ended|
Dec. 31, 2016
14. Research Agreement
In November 2014, the Company entered into a research agreement with a multinational pharmaceutical company (the ‘‘Counterparty’’) for purposes of mapping immune cell super-enhancers (‘‘SE’’) and transcriptional targets in autoimmune disease. Under the research agreement, the Company is responsible for the conduct of all activities under separate projects, as defined in the research agreement, associated with generating SE and transcriptional maps of the cell/tissue supplied by the Counterparty. Upon the completion of each project, the Counterparty determines whether to commence the next project under the research agreement upon written notification.
The research agreement was amended in November 2016 to extend the term to March 31, 2017. The research agreement terminates automatically if the Counterparty does not notify the Company that it would like to commence the next research project.
In exchange for these research services, the Company may receive funding of up to $3.0 million over the term of the agreement. The Company will recognize revenue on a completed performance basis for each project performed under the agreement, as the Company does not have the ability to reasonably estimate the period of performance and the final study report for each project is significant to the overall arrangement. The Company recognized revenue of $0.3 million during each of the years ended December 31, 2016 and December 31, 2015 under the agreement.
Research Agreement [Abstract]
No definition available.
The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.
Reference 1: http://www.xbrl.org/2003/role/presentationRef